Current status of clinical background of patients with atrial fibrillation in a community-based survey: The Fushimi AF Registry

Akao, Masaharu; Yuan, Chun; Wada, Hiromichi; Esato, Masahiro; Hashimoto, Takeji; Abe, Mitsuru; Hasegawa, Koji; Tsuji, Hikari; Furuke, Keizo

doi:10.1016/j.jjcc.2012.12.002

Cited by 208 publications

(179 citation statements)

References 21 publications

Supporting

Mentioning

165

Contrasting

Unclassified

Order By: Relevance

“…In the era of warfarin, OAC was overused for low-risk patients, and also underused for high-risk patients. 9 After the release of DOAC, the total prevalence of OAC increased gradually, but use of OAC increased predominantly in low-risk patients. This suggests that the 23 Use of under-dose DOAC is common in real-world clinical practice, and although it may have a more favorable bleeding profile, it may also result in insufficient stroke prevention.…”

Section: Discussionmentioning

confidence: 99%

Current Status and Outcomes of Direct Oral Anticoagulant Use in Real-World Atrial Fibrillation Patients　― Fushimi AF Registry ―

Yamashita

Uozumi

Hamatani

et al. 2017

Circ J

Self Cite

121

102

View full text Add to dashboard Cite

practice, DOAC have prevailed all over the world. After the release of DOAC, several national guidelines for the management of AF were updated, and now recommend DOAC as broadly preferable to VKA in the vast majority of patients with non-valvular AF. 6 RCT, however, are conducted under idealized and rigorously controlled conditions. Thus, RCT patients are highly selected, and hence are not broadly representative of real-world patients. Also, not many studies have investigated the real-world effectiveness and safety of DOAC in unselected patients; and, according to studies involving general practice settings, the outcomes of DOAC in real-world clinical practice do not necessarily coincide with the RCT outcomes. 7, 8 The aim of this study was therefore to evaluate the change in OAC status over time and the clinical outcomes O ral anticoagulants (OAC) are essential for stroke prevention in patients with atrial fibrillation (AF). The use of conventional OAC, such as a vitamin K antagonist (VKA), reduces stroke by 64%, compared with non-VKA users. 1 Until recently, VKA were the only available OAC but direct oral anticoagulants (DOAC; dabigatran, rivaroxaban, apixaban, and edoxaban) have been introduced for stroke prevention in patients with AF. Recent large-scale randomized clinical trials (RCT) demonstrated the similar efficacy and safety of DOAC, compared with VKA.

show abstract

Section: Discussionmentioning

confidence: 99%

Current Status and Outcomes of Direct Oral Anticoagulant Use in Real-World Atrial Fibrillation Patients　― Fushimi AF Registry ―

Yamashita

Uozumi

Hamatani

et al. 2017

Circ J

Self Cite

121

102

View full text Add to dashboard Cite

show abstract

“…13 The inclusion criterion for the registry is the documentation of AF on 12- BW was recorded to the nearest 100 g and the data were collected at the time of entry into the registry. We defined LBW as ≤50 kg.…”

Section: Methodsmentioning

confidence: 99%

Low Body Weight Is Associated With the Incidence of Stroke in Atrial Fibrillation Patients　– Insight From the Fushimi AF Registry –

Hamatani

Ogawa

Uozumi

et al. 2015

Circ J

Self Cite

View full text Add to dashboard Cite

“…11 The inclusion criterion for the registry is the documentation of AF on 12-lead ECG or Holter monitoring at any time. There are no exclusion criteria.…”

Section: Methodsmentioning

confidence: 99%

Inappropriate Use of Oral Anticoagulants for Patients With Atrial Fibrillation

Akao

Yuan

Esato

et al. 2014

Circ J

Self Cite

127

View full text Add to dashboard Cite

Current status of clinical background of patients with atrial fibrillation in a community-based survey: The Fushimi AF Registry

Abstract: The Fushimi AF Registry provides a unique snapshot of current AF management in an urban community in Japan.

Cited by 208 publications

References 21 publications

Current Status and Outcomes of Direct Oral Anticoagulant Use in Real-World Atrial Fibrillation Patients　― Fushimi AF Registry ―

Current Status and Outcomes of Direct Oral Anticoagulant Use in Real-World Atrial Fibrillation Patients　― Fushimi AF Registry ―

Low Body Weight Is Associated With the Incidence of Stroke in Atrial Fibrillation Patients　– Insight From the Fushimi AF Registry –

Inappropriate Use of Oral Anticoagulants for Patients With Atrial Fibrillation

Contact Info

Product

Resources

About

Current status of clinical background of patients with atrial fibrillation in a community-based survey: The Fushimi AF Registry

Abstract: The Fushimi AF Registry provides a unique snapshot of current AF management in an urban community in Japan.

Cited by 208 publications

References 21 publications

Current Status and Outcomes of Direct Oral Anticoagulant Use in Real-World Atrial Fibrillation Patients ― Fushimi AF Registry ―

Current Status and Outcomes of Direct Oral Anticoagulant Use in Real-World Atrial Fibrillation Patients ― Fushimi AF Registry ―

Low Body Weight Is Associated With the Incidence of Stroke in Atrial Fibrillation Patients – Insight From the Fushimi AF Registry –

Inappropriate Use of Oral Anticoagulants for Patients With Atrial Fibrillation

Contact Info

Product

Resources

About

Current Status and Outcomes of Direct Oral Anticoagulant Use in Real-World Atrial Fibrillation Patients　― Fushimi AF Registry ―

Current Status and Outcomes of Direct Oral Anticoagulant Use in Real-World Atrial Fibrillation Patients　― Fushimi AF Registry ―

Low Body Weight Is Associated With the Incidence of Stroke in Atrial Fibrillation Patients　– Insight From the Fushimi AF Registry –